keyword
MENU ▼
Read by QxMD icon Read
search

EASL

keyword
https://www.readbyqxmd.com/read/29777749/burden-of-liver-disease-in-europe-epidemiology-and-analysis-of-risk-factors-to-identify-prevention-policies
#1
REVIEW
Laura Pimpin, Helena Cortez-Pinto, Francesco Negro, Emily Corbould, Jeffrey V Lazarus, Laura Webber, Nick Sheron
BACKGROUND & AIMS: The burden of liver disease in Europe continues to grow. We aimed to describe the epidemiology of liver diseases and their risk factors in European countries, and identify public health interventions that could impact on these risk factors to reduce the burden of liver disease. METHODS: As part of the HEPAHEALTH project, commissioned by EASL, we extracted information on historical and current prevalence and mortality from national and international literature and databases on liver disease in 35 countries in the WHO European region, as well as historical and recent prevalence data on their main determinants; alcohol consumption, obesity and hepatitis B and C virus infections...
May 16, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29773899/management-of-acute-hcv-infection-in-the-era-of-direct-acting-antiviral-therapy
#2
REVIEW
Marianne Martinello, Behzad Hajarizadeh, Jason Grebely, Gregory J Dore, Gail V Matthews
The management of acute HCV infection has not been standardized following the availability of direct-acting antiviral agents (DAAs) for chronic HCV infection, and substantial uncertainty exists regarding the optimal treatment regimen and duration. Despite the lack of direct evidence, the 2016 American Association for the Study of Liver Diseases (AASLD)-Infectious Diseases Society of America (IDSA) guidelines supported "the same regimens for acute HCV as recommended for chronic HCV infection … owing to high efficacy and safety", whereas the 2016 European Association for the Study of the Liver (EASL) guidelines recommended sofosbuvir-ledipasvir, sofosbuvir-velpatasvir or sofosbuvir plus daclatasvir for 8 weeks in acute HCV infection, with a longer duration of 12 weeks recommended for those infected with HIV and/or baseline HCV RNA levels >1,000,000 IU/ml...
May 17, 2018: Nature Reviews. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29771862/efficacy-and-safety-of-direct-acting-antiviral-therapy-for-chronic-hepatitis-c-in-thalassemic-children
#3
Shivadatta Padhi, Sudhir Maharshi, Gaurav K Gupta, Kapil Garg, Sandeep Nijhawan
OBJECTIVES: There is limited data on the efficacy and safety of directly acting antiviral therapy (DAA) for chronic hepatitis C in pediatric population. The aim was to assess the efficacy and safety of DAA in chronic hepatitis C β-thalassemic major pediatric patients. METHODS: Prospective study was conducted from September 2015 to January 2017. All β-thalassemic major chronic hepatitis C pediatric patients with age between 5 and 14 years were included in this study...
May 16, 2018: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/29755781/prolonged-survival-of-metastatic-hepatocellular-carcinoma-a-case-report
#4
Nadiah Zainal, Harissa Husainy Hasbullah
Management of hepatocellular carcinoma (HCC) generally follows EASL-EORTC clinical practise guideline. We report a case of a 50-year-old man who had multinodular HCC with lung metastases, whose management had deviated from the standard guideline but still survive 5 years after initial diagnosis.
April 2018: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29735787/a-dynamic-model-for-predicting-outcome-in-patients-with-hbv-related-acute-on-chronic-liver-failure
#5
Wei Lin, Jing Zhang, Xiaohui Liu, Hongqun Liu, Jinqiu He, Ming Li, Shuqin Zhang, Yuexin Zhang, Hong Chen, Changqing Zhang, Wenfang Wu, Chenggang Jin, Samuel S Lee, Zhongping Duan
INTRODUCTION AND AIM: Accurately predicting the prognosis of individual patient is crucial in the management of ACLF. We aimed to establish a specific prognostic model for HBV-related ACLF patients treated with nucleoside analog (NA). MATERIAL AND METHODS: We prospectively collected 205 ACLF cases diagnosed according to the APASL criteria. A dynamic prognostic model based on APASL criteria was established and validated. To demonstrate that the model is also applicable to those within EASL criteria, we divided the patients into two groups: met APASL criteria only (group A, n = 123); met both APASL and EASL criteria (group B, n = 82)...
April 9, 2018: Annals of Hepatology
https://www.readbyqxmd.com/read/29716179/recent-update-of-the-2017-korean-association-for-the-study-of-the-liver-kasl-treatment-guidelines-of-chronic-hepatitis-c-comparison-of-guidelines-from-other-continents-2017-aasld-idsa-and-2016-easl
#6
Jong Eun Yeon
The paradigm for the treatment of chronic hepatitis C (CHC) has been changed due to the development of direct acting antivirals (DAAs) of hepatitis C virus (HCV). The high sustained virologic response rate and ease of administration makes the DAAs approach ideal to contribute to the complete eradication of HCV. Currently, treatment options for individual patients vary depending on the genotype or subtype of HCV, presence or absence of liver cirrhosis, previous experience of antiviral treatment or resistance associated substitutions...
May 2, 2018: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/29688155/radiation-segmentectomy-potential-curative-therapy-for-early-hepatocellular-carcinoma
#7
Robert J Lewandowski, Ahmed Gabr, Nadine Abouchaleh, Rehan Ali, Ali Al Asadi, Ronald A Mora, Laura Kulik, Daniel Ganger, Kush Desai, Bartley Thornburg, Samdeep Mouli, Ryan Hickey, Juan Carlos Caicedo, Michael Abecassis, Ahsun Riaz, Riad Salem
Purpose To report long-term outcomes of radiation segmentectomy (RS) for early hepatocellular carcinoma (HCC). The authors hypothesized that outcomes are comparable to curative treatments for patients with solitary HCC less than or equal to 5 cm and preserved liver function. Materials and Methods This retrospective study included 70 patients (median age, 71 years; range, 22-96 years) with solitary HCC less than or equal to 5 cm not amenable to percutaneous ablation who underwent RS (dose of >190 Gy) between 2003 and 2016...
April 24, 2018: Radiology
https://www.readbyqxmd.com/read/29650333/easl-recommendations-on-treatment-of-hepatitis-c-2018
#8
(no author information available yet)
No abstract text is available yet for this article.
April 9, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29628281/easl-clinical-practice-guidelines-management-of-hepatocellular-carcinoma
#9
(no author information available yet)
No abstract text is available yet for this article.
April 5, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29628280/easl-clinical-practice-guidelines-management-of-alcohol-related-liver-disease
#10
(no author information available yet)
No abstract text is available yet for this article.
April 5, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29621059/presence-of-hepatitis-b-surface-antibody-in-addition-to-hepatitis-b-core-antibody-confers-protection-against-hepatitis-b-virus-infection-in-hepatitis-b-surface-antigen-negative-patients-undergoing-kidney-transplantation
#11
Jae Wan Jeon, So Mi Kim, Hyungjin Cho, Chung Hee Baek, Hyosang Kim, Sung Shin, Young Hoon Kim, Duck Jong Han, Soon Bae Kim
BACKGROUND: The American Gastroenterological Association (AGA) and European Association for the Study of the Liver (EASL) recommend that hepatitis B surface antigen (HBsAg)-negative and hepatitis B core antibody (anti-HBc)-positive patients who receive immunosuppression should be monitored for hepatitis B virus (HBV) infection regardless of hepatitis B surface antibody (anti-HBs) status. However, anti-HBs may provide protection against infection. To investigate whether the presence of anti-HBs in addition to anti-HBc confers protection, we classified HBsAg(-) kidney transplantation (KT) patients into 4 groups according to anti-HBc and anti-HBs status, and compared the HBV infection rate between the anti-HBc(+)anti-HBs(+) group and the other 3 groups...
April 5, 2018: Transplantation
https://www.readbyqxmd.com/read/29609832/easl-clinical-practice-guidelines-on-hepatitis-e-virus-infection
#12
(no author information available yet)
Infection with hepatitis E virus (HEV) is a significant cause of morbidity and mortality, representing an important global health problem. Our understanding of HEV has changed completely over the past decade. Previously, HEV was thought to be limited to certain developing countries. We now know that HEV is endemic in most high-income countries and is largely a zoonotic infection. Given the paradigm shift in our understanding of zoonotic HEV and that locally acquired HEV is now the commonest cause of acute viral hepatitis in many European countries, the focus of these Clinical Practice Guidelines will be on HEV genotype 3 (and 4)...
March 31, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29570560/dual-sofosbuvir-daclatasvir-therapy-in-adolescent-patients-with-chronic-hepatitis-c-infection
#13
Mostafa Yakoot, Mortada H El-Shabrawi, Manal M AbdElgawad, Aml A Mahfouz, Sherine Helmy, Alaa M Abdo, Hisham R El-Khayat
OBJECTIVES: Dual sofosbuvir/daclatasvir (SOF/DCV) therapy is currently recommended by The European Association for Study of Liver (EASL) as an option for the treatment of chronic hepatitis C virus infection (HCV) in adults for all genotypes; however it is still not considered for patients younger than 18 years old. We aimed to test safety and efficacy of SOF/DCV in adolescent patients 12 to 17 years old with chronic HCV, genotype 4 infection. METHODS: We conducted a prospective, uncontrolled, open-label multicenter study...
March 22, 2018: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/29570559/the-health-care-transition-of-youth-with-liver-disease-into-the-adult-health-system-position-paper-from-espghan-and-easl
#14
Pietro Vajro, Björn Fischler, Patrizia Burra, Dominique Debray, Antal Dezsofi, Salvatore Guercio Nuzio, Nedim Hadzic, Loreto Hierro, Joerg Jahnel, Thierry Lamireau, Patrick McKiernan, Valerie McLin, Valerio Nobili, Piotr Socha, Francoise Smets, Ulli Baumann, Henkjan J Verkade
BACKGROUND: Medical advances have dramatically improved the long-term prognosis of children and adolescents with once-fatal hepatobiliary diseases. However, there is no generally accepted optimal pathway of care for the transition from paediatric care to the adult health system. AIM: The purpose of this position paper is to propose a transition process for young people with paediatric onset hepatobiliary diseases from child-centred to adult-centred healthcare services...
March 22, 2018: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/29570181/-benign-liver-tumours-current-diagnostics-and-therapeutic-modalities
#15
Gergely Nagy, Katalin Dezsõ, Gergely Kiss, Zsuzsanna Gerlei, Péter Nagy, László Kóbori
The most common benign liver tumours are haemangiomas, focal nodular hyperplasia and hepatocellular adenoma. We perform a review of the literature and show the current diagnostic and therapeutic modalities based on the EASL Clinical Practice Guideline. With the widespread use of ultrasound, the detection of liver lesions is increased. They are usually found in women of childbearing age with atypical abdominal pain or incidentally. Contrast-enhanced US, CT or MRI are usually necessary for differential diagnosis...
March 23, 2018: Magyar Onkologia
https://www.readbyqxmd.com/read/29545380/retrospective-voxel-based-dosimetry-for-assessing-the-body-surface-area-model-ability-to-predict-delivered-dose-and-radioembolization-outcome
#16
Marilyne Kafrouni, Carole Allimant, Marjolaine Fourcade, Sébastien Vauclin, Julien Delicque, Alina-Diana Ilonca, Boris Guiu, Federico Manna, Nicolas Molinari, Denis Mariano-Goulart, Fayçal Ben Bouallègue
The aim of this study was to quantitatively evaluate the body surface area (BSA) model ability to predict tumor absorbed dose and treatment outcome through retrospective voxel-based dosimetry. Methods: Data from thirty-five hepatocellular carcinoma patients with a total of forty-two resin microsphere radioembolization treatments were included. Injected activity was planned with the BSA model. Voxel dosimetry based on 99m Tc-labeled macroaggregated albumin SPECT and 90 Y-microsphere PET was retrospectively performed using a dedicated treatment planning system (PLANET® Dose, DOSIsoft SA, Cachan, France)...
March 15, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29505844/hepatitis-c-virus-eradication-by-direct-acting-antiviral-agents-improves-carotid-atherosclerosis-in-patients-with-severe-liver-fibrosis
#17
Salvatore Petta, Luigi Elio Adinolfi, Anna Ludovica Fracanzani, Francesca Rini, Rosalia Caldarella, Vincenza Calvaruso, Calogero Cammà, Marcello Ciaccio, Vito Di Marco, Stefania Grimaudo, Anna Licata, Aldo Marrone, Riccardo Nevola, Rosaria Maria Pipitone, Antonio Pinto, Luca Rinaldi, Daniele Torres, Antonino Tuttolomondo, Luca Valenti, Silvia Fargion, Antonio Craxì
BACKGROUND AND AIMS: Recent studies suggest an association between hepatitis C virus (HCV) infection and cardiovascular damage, including carotid atherosclerosis, with a possible effect of HCV clearance on cardiovascular outcomes. We aimed to examine whether HCV eradication by direct-acting antiviral agents (DAA) improves carotid atherosclerosis in HCV-infected patients with advanced fibrosis/compensated cirrhosis. MATERIALS AND METHODS: One hundred eighty-two consecutive patients with HCV and advanced fibrosis or compensated cirrhosis were evaluated...
March 2, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29495116/reproducibility-of-european-association-for-the-study-of-the-liver-criteria-and-modified-response-evaluation-criteria-in-solid-tumors-in-patients-treated-with-sorafenib
#18
Mi Young Jeon, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Song-Ee Baek, Hye Soo Kim, Seung Up Kim, Mi Suk Park
BACKGROUND & AIMS: The European Association for the Study of the Liver criteria and the modified Response Evaluation Criteria in Solid Tumors are used for assessing the treatment outcomes of hepatocellular carcinoma. We investigated the inter- and intra-observer reproducibility of the European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients with advanced hepatocellular carcinoma treated with sorafenib. METHODS: A total of 99 patients with treatment-naive advanced hepatocellular carcinoma receiving sorafenib were included...
March 1, 2018: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29427481/treatment-of-hepatitis-c-results-in-real-life
#19
REVIEW
Christophe Hézode
Direct-acting antivirals (DAAs) have transformed traditional treatment options for hepatitis C virus (HCV) infection. DAA combinations have been shown to be highly effective in reducing the burden of chronic HCV infection in clinical trials and have been recommended by the European Association for the Study of the Liver (EASL) treatment guidelines. This review examines the results of second-generation DAA combinations in real-life clinical practice in patients with genotypes 1-3 and in those co-infected with HIV (real-world data in genotypes 4-6 are rare)...
February 2018: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29391267/association-between-grade-of-acute-on-chronic-liver-failure-and-response-to-terlipressin-and-albumin-in-patients-with-hepatorenal-syndrome
#20
Salvatore Piano, Hartmut H Schmidt, Xavier Ariza, Alex Amoros, Antonietta Romano, Anna Hüsing-Kabar, Elsa Solà, Alexander Gerbes, Mauro Bernardi, Carlo Alessandria, Bernhard Scheiner, Marta Tonon, Miriam Maschmeier, Cristina Solè, Jonel Trebicka, Thierry Gustot, Frederik Nevens, Vicente Arroyo, Pere Gines, Paolo Angeli
BACKGROUND & AIMS: Type 1 hepatorenal syndrome (HRS) is the most high-risk type of renal failure in patients with cirrhosis. Terlipressin and albumin are effective treatments for type 1 HRS. However, the effects of acute on chronic liver failure (ACLF) grade on response to treatment are not clear. We aimed to identify factors associated with response to treatment with terlipressin and albumin in patients with type 1 HRS (reduction in serum level of creatinine to below 1.5 mg/dL at the end of treatment) and factors associated with death within 90 days of HRS diagnosis (90-day mortality)...
January 31, 2018: Clinical Gastroenterology and Hepatology
keyword
keyword
49385
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"